Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II randomized multicenter study of estramustine phosphate in HER2-negative, hormone receptor-positive metastatic breast cancer after aromatase inhibitor treatment
2009-017788-40Phase 2Active
- Sponsor
- Institut de Cancérologie de Lorraine
- Start
- Sep 2010
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of estramustine in breast cancer (2 arms), sponsored by Institut de Cancérologie de Lorraine. Primary endpoint: Proportion of patients progression-free at 6 months. Started Sep 2010; status: active.
02
Drugs
estramustine
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2009-017788-40.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-017788-40.